Do grape polyphenols improve metabolic syndrome components? A systematic review
J Woerdeman1, E van Poelgeest2, J C F Ket3,4
1Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
European Journal of Clinical Nutrition
|February 2, 2017
Summary
Grape polyphenols show limited effects on metabolic syndrome components in humans. While some evidence suggests potential improvements in insulin sensitivity, compelling data for blood sugar, blood pressure, or lipid levels are lacking.
Area of Science:
- Nutrition Science
- Cardiovascular Health
- Metabolic Disorders
Background:
- Grape polyphenols, found in wine, show promise for metabolic syndrome in preclinical studies.
- Human trial evidence on grape polyphenol efficacy for metabolic syndrome remains controversial.
Purpose of the Study:
- To systematically review human clinical trials on grape polyphenols and metabolic syndrome components.
- To assess effects on insulin sensitivity, glycemia, blood pressure, and lipid levels.
Main Methods:
- Systematic literature search of Medline, EMBASE, and Cochrane databases.
- Inclusion of all clinical trials assessing grape polyphenols' impact on metabolic markers.
- Quality assessment using the Jadad scale by two independent reviewers.
Main Results:
- Thirty-nine studies were included; many were low-quality.
- Limited evidence suggests grape polyphenols may improve insulin sensitivity.
- No compelling data support effects on glycemia, blood pressure, or lipid levels.
Conclusions:
- Current evidence does not strongly support grape polyphenols for improving glycemia, blood pressure, or lipid levels in humans.
- Further high-quality research is needed to confirm potential benefits for insulin sensitivity.
More Related Videos
12:00Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
20.0K
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.9K
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
769
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
769
01:19Overview of Carbohydrate Metabolism
4.0K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
4.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
713
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
713
01:26Atherosclerosis III: Management
540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
01:23Dipeptidyl Peptidase 4 Inhibitors
821
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
821
01:16Hormones Regulating Blood Glucose
7.8K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.8K